Fig. 3From: Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world studyKaplan-Meier curve of PFS (A) in the RC48 plus ICIs and RC48 population. Kaplan-Meier curve of PFS (B) in the HER2 positive and HER2-low populationBack to article page